Menu Search
Equities

Novartis AG

NOVNEE:SWX

Novartis AG

Actions
  • Price (CHF)91.48
  • Today's Change0.63 / 0.69%
  • Shares traded400.00k
  • 1 Year change+7.35%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 15:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NOVN:SWX since
announced		Transaction
value
Mariana Oncology IncAnnounced02 May 202402 May 2024Announced2.82%1.75bn
IFM Due IncAnnounced13 Mar 202413 Mar 2024Announced4.53%835.00m
Cytokinetics IncRumoured08 Jan 202408 Jan 2024Rumoured1.27%--
Calypso Biotech BVAnnounced08 Jan 202408 Jan 2024Announced1.27%425.00m
SanReno TherapeuticsDeal completed05 Jan 202405 Jan 2024Deal completed1.91%--
Data delayed at least 15 minutes, as of Nov 21 2024 16:36 GMT.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
MFS International (UK) Ltd.as of 30 Sep 20242.59m0.00%
GAM Investment Management (Switzerland) AGas of 30 Sep 2024435.00k0.00%
Massachusetts Financial Services Co.as of 30 Sep 2024310.01k0.00%
LUKB Expert Fondsleitung AGas of 31 Jul 202482.29k0.00%
Pyrford International Ltd.as of 31 Dec 202379.13k0.00%
Voya Investment Management Co. LLCas of 30 Sep 202444.81k0.00%
Swiss Rock Asset Management AGas of 30 Jun 202319.61k0.00%
N.F.U. Mutual Unit Managers Ltd.as of 30 Jun 202318.42k0.00%
Nomura Asset Management Co., Ltd.as of 31 Oct 202411.04k0.00%
Skyblue Fund Managers (Pty) Ltd.as of 31 Mar 20246.00k0.00%
More ▼
Data from 30 Jun 2023 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.